Top

Published in:

01-01-2012 | Letter to the Editor

Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients

Authors: Satoru Takeuchi, Kojiro Wada, Kimihiro Nagatani, Naoki Otani, Hideo Osada, Hiroshi Nawashiro

Published in: Acta Neurochirurgica | Issue 1/2012

Excerpt

Vergouwen et al. reported that intravenous tissue plasminogen activator (IV tPA) treatment was not associated with an increased risk of secondary intracerebral hemorrhage or gastrointestinal hemorrhage in patients with acute ischemic stroke taking warfarin with an international normalized ratio (INR) <1.7 [6]. These results mean that IV tPA treatment should not be discouraged in patients taking warfarin with INR <1.7. …

Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M (2010) Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 8:790–798CrossRef

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef

De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R (2010) Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 30:533–534PubMedCrossRef

Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:527–537PubMedCrossRef

Matute MC, Guillán M, García-Caldentey J, Buisan J, Aparicio M, Masjuan J, Alonso de Leciñana M (2011) Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 106:178–179PubMedCrossRef

Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK, Silver FL, Investigators of the Registry of the Canadian Stroke Network (2011) Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 42:1041–1045PubMedCrossRef

Title: Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients
Authors: Satoru Takeuchi
Kojiro Wada
Kimihiro Nagatani
Naoki Otani
Hideo Osada
Hiroshi Nawashiro
Publication date: 01-01-2012
Publisher: Springer Vienna
Published in: Acta Neurochirurgica / Issue 1/2012
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-011-1196-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Traumatic subarachnoid hemorrhage, basal ganglia hematoma and ischemic stroke caused by a torn lenticulostriate artery

Arteriovenous malformation of the pineal gland

A. R. Vaccaro, J. C. Eck (eds): Controversies in spine surgery: best evidence recommendations

Neuroembolization may expose patients to radiation doses previously linked to tumor induction

Clinical relevance of blast-related traumatic brain injury

The effect of common carotid artery occlusion on delayed brain tissue damage in the rat double subarachnoid hemorrhage model